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Abstract 
A new rapid, simple, sensitive, selective and accurate reversed-phase stability-
indicating Ultra Performance Liquid Chromatography (RP-UPLC) technique was 
developed for the assay of Tolterodine Tartrate in pharmaceutical dosage form, 
human plasma and urine samples. The developed UPLC method is superior in 
technology to conventional HPLC with respect to speed, solvent consumption, 
resolution and cost of analysis. Chromatographic run time was 6 min in 
reversed-phase mode and ultraviolet detection was carried out at 220 nm for 
quantification.  Efficient separation was achieved for all the degradants of 
Tolterodine Tartrate on BEH C18 sub-2-μm Acquity UPLC column using 
Trifluoroacetic acid  and  acetonitrile as organic solvent in a linear gradient 
program.  The active pharmaceutical ingredient was extracted from tablet 
dosage form using a mixture of acetonitrile and water as diluent. The calibration 
graphs were linear and the method showed excellent recoveries for bulk and 
tablet dosage form. The test solution was found to be stable for 40 days when 
stored in the refrigerator between 2 and 8 °C. The developed UPLC method 
was validated and meets the requirements delineated by the International 
Conference on Harmonization (ICH) guidelines with respect to linearity, 102  R. Yanamandra et al.:   
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accuracy, precision, specificity and robustness.  The intra-day and inter-day 
variation was found be less than 1%.  The method was reproducible and 
selective for the estimation of Tolterodine Tartrate. Because the method could 
effectively separate the drug from its degradation products, it can be employed 
as a stability-indicating one.  
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Introduction 
Ultra Performance Liquid Chromatography (UPLC) system is an innovative technique that 
brought revolution in high performance liquid chromatography by outperforming 
conventional HPLC. UPLC decreases sample run times up to a factor of 10, uses up to 
95% less solvent and significantly improves productivity in the lab as compared to HPLC. 
The sub-2-μm  hybrid  particle  chemistry,  which  offers  significant  benefits  over  today's 
HPLC systems,  equipped with standard 5-μm  particle  chemistries. UPLC achieves the 
speed by using novel sub two-micron particles that reduce chromatographic run times and 
improve resolution.  
UPLC was designed as a total system to leverage both ultra-high pressure and small 
particle separation attributes that result in uniquely superior performance with significant 
improvements in resolution, sensitivity and speed. UPLC system allows chromatographers 
to work at higher efficiencies with a much wider range of linear velocities, flow rates and 
backpressures. UPLC Photodiode Array (PDA) Detector detects and quantifies lower 
concentrations of sample analyte and trace impurities with maximum sensitivity. The 
present study was conducted to quantify Tolterodine Tartrate in pharmaceutical dosage 
form, human plasma and in urine samples by using RP-UPLC technique. 
Tolterodine Tartrate (TTT) (CAS NO: 124937-52-6), 2-[3-(di-iso-propylamino)-1-phenyl-
propyl]-4-methylphenol, is listed in the Merck Index [1] and exists in two isomeric forms (R) 
and (S). It is not official in IP, BP and USP. Tolterodine Tartrate is a potent muscarinic 
receptor antagonist used in the treatment of urinary urge incontinence and other 
symptoms of an overactive bladder [2]. Various spectrophotometric methods [3, 4] and a 
few HPLC analytical methods for the stability-indicating and quantification of Tolterodine 
[5–7] and in plasma [8–11] for dosage form have been reported. An enantio-specific HPLC 
method for the determination of (S)-enantiomer impurities in (R)-Tolterodine Tartrate [12] 
and a validated chiral HPLC method for the separation of enantiomers  [13], HPLC 
analytical method for the determination of related substances [14–16] have been reported. 
TTT is available in the commercial market in tablet and capsule dosage form by different 
manufacturers. Present study involves a new rapid, sensitive and validated UPLC method 
for the assay of TTT for tablet dosage form and its application in spiked human plasma 
and urine samples. 
A review of the literature did not reveal the presence of assay of TTT dosage form by 
using UPLC technique. The reported HPLC methods are more time consuming, complex 
mobile phase mixtures, use high flow rate of analysis, lack of sensitivity and peak   A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate  103 
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symmetry, and not compatible to LC-MS technique. The aim of this work was to develop a 
suitable UPLC method for the assay of TTT by using UV detection which is fast, uses less 
flow rate, less time consuming with better sensitivity, peak symmetry and is compatible 
with LC-MS technique thus able to provide additional structural information. The developed 
assay method can quantify TTT in tablet dosage form in the presence of its degradation 









Fig. 1.   Structure of Tolterodine Tartrate 
Experimental  
Chemicals  
Bulk sample of Tolterodine Tartrate was obtained from Inogent Laboratories Ltd., 
(Hyderabad, India). Commercially available Roliten manufacture by Ranbaxy Laboratories 
Ltd. was purchased from a local pharmacy containing Tolterodine Tartrate (2 mg). HPLC 
grade  acetonitrile  was obtained from Apchem, Ashonuj Chem Pvt. Ltd (Navi Mumbai, 
India). Trifluoroacetic acid (TFA) spectroscopy grade was purchased from Merck 
(Darmstadt, Germany). High purity water was obtained from Millipore Milli-Q Plus water 
purification system. Acquity BEH-C18 and BEH-Shield RP18 columns were purchased 
from Waters.  
Equipment  
The LC system used for method development and method validation consisted of a 
Waters Acquity UPLC with PDA Detector with a separation module. Empower software 
(Waters) was used for data handling installed on a Pentium computer (Lenovo).  
Chromatographic Conditions  
The analysis was carried out on Acquity BEH C18 column 100 mm X 2.1 mm, 1.7μm. The 
mobile phase composition was 0.025% TFA (aqueous) buffer as mobile phase A and 
0.025% TFA in Acetonitrile as  mobile phase B which was filtered through 0.45 µm 
membrane filter and sonicated for 15 min. A linear time gradient program [Time/%B: 0/30, 
4/80, 6/80, 6.1/30] at a flow rate of 0.30 mL min
−1, detection at 220 nm, and 
chromatographic run time of 6.0 min was used. The injection volume was 3.0 μL, a mixture 
of Acetonitrile and Water (50:50, v/v) was used as diluent. Prior to injection of the drug 
solution, the column was equilibrated for at least 15 min with the initial time gradient 
mobile phase conditions flowing through the system. 
 
 104  R. Yanamandra et al.:   
Sci Pharm. 2012; 80: 101–114 
Preparation of Solutions  
Preparation of Standard Solution  
Bulk Standard of TTT was prepared by dissolving 20 mg in 100 mL standard volumetric 
flask containing approximately 50 mL of diluent and the solution was sonicated for 10 min, 
and the volume was made up to the mark with diluent to obtain a concentration of 200 
μg mL
−1.  Subsequent dilution of this solution was made with diluent to obtain the 
concentration of 40 μg mL
−1. 
Preparation of Sample Solution  
Ten tablets were weighed to determine the average tablet weight and powdered in a 
mortar. Powder equivalent to 20 mg of TTT was transferred into a 100 mL volumetric flask. 
About 50 mL of diluent was added and kept on a rotary shaker for 20 min to disperse the 
material completely, followed by sonication for 10 min, cooled to room temperature, made 
up to mark with diluent and mixed well. About 25 mL of sample solution was centrifuged 
for 15 min at 2,500 rpm. The sample solution was filtered through a 0.45 μm Nylon-66 
membrane syringe filter, and 10.0 mL of this solution was taken in a 50 mL volumetric flask 
and made up to volume with diluent. 
Plasma drug sample preparation and extraction, and urine sample preparation 
Blood samples were collected from healthy volunteers and then centrifuged at 5000 rpm 
for 10 min. The supernatant  obtained  was  stored  at  −20 °C.  After thawing, plasma 
samples are spiked with working solutions to produce desired concentrations of the drug. 
To 0.5 mL of TTT spiked plasma solution added 2.5 mL of extraction solvent [Ethyl 
Acetate:n-Hexane, 70:30 v/v], cyclomixed for 10 min and centrifuged the sample solution 
for 10 min at 2500 rpm. 2 mL of supernatant  layer was taken and evaporated under 
Nitrogen at 50 °C for 20 min and reconstitute the sample with 0.5 mL of diluent. A 3.0 μL 
volume of each sample was injected and chromatographed under the above conditions. 
Method Validation  
Method validation was performed according to International Conference on Harmonization 
(ICH) guidelines with respect to precision, linearity, accuracy, specificity and robustness 
[17]. 
Precision  
The precision of the developed method was evaluated by six replicate injections of the 
above standard mixture. The RSD (Relative Standard Deviation) was evaluated for peak 
areas, USP (United States of Pharmacopeia) tailing factor and plate count for TTT. The 
intermediate precision of the method was also evaluated on a different column.  
Linearity and range 
Stock solution TTT 200 μg mL
−1 was prepared by dissolving the appropriate amount in 100 
mL of diluent and further diluted to the required concentrations with diluent. The solution 
was prepared at six concentration levels ranging from 25% to 150% of the target 
concentration 40 μg mL
−1. Linearity of the method was studied by injecting six 
concentrations of the drug prepared in the diluent in triplicate into the UPLC system 
keeping the injection volume constant.  The peak areas were plotted against the   A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate  105 
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corresponding concentrations to obtain the calibration graphs. The correlation coefficients, 
slopes and Y-intercepts of the calibration curve were determined.  
Accuracy  
Standard addition and recovery experiments were conducted to determine accuracy of the 
method for the quantification of TTT. The study was carried out at 50%, 100% and 150% 
for three replicate injections of each concentration of the analyte followed by calculation of 
the percentage recovery.  
Solution Stability and Mobile Phase Stability  
Solution stability of TTT in a tightly capped volumetric flask for 40 days when stored in a 
refrigerator between 2 to 8 °C temperature was studied and the content of the drug was 
determined. Mobile phase stability was assessed over a period of 72 h by injecting the 
freshly prepared sample solutions in 8 h interval. The content of the drug was determined 
in the test solution.  
Specificity  
The specificity of the analytical method was checked in different conditions of acid 
hydrolysis (0.1M HCl), base hydrolysis (0.1M NaOH) and peroxide treatment (0.3% H2O2). 
Aliquot quantity of TTT stock solution was taken in different volumetric flasks and added 
3.0 mL of 0.1M HCl (0.018%), 3.0 mL of 0.1M NaOH (0.024%), and 1.0 mL of 0.3% H2O2 
(0.006%) respectively and diluted to 50 mL with diluent. These solutions were refluxed at 
80 °C for 3 h, 6 h and 8 h, cooled to room temperature, made up to 100 mL with diluent 
and analyzed by UPLC.  
Robustness & Ruggedness 
The experimental conditions were deliberately altered and the impact on retention time, 
peak asymmetry and % assay was evaluated by changing flow rate, buffer concentration, 
column temperature, buffer pH and mobile phase composition. The effect of different 
column, different analyst, and different system was also studied as part of the ruggedness 
of the method. 
Plasma and Urine drug analysis 
The availability of TTT in tablet dosage form in human plasma and urine was determined 
by the stated chromatographic conditions. Blood samples of healthy volunteers (age group 
between 23–26 years, non-smokers, and not taking any other medicines) were collected. 
Multiple blood samples were collected in evacuated glass tubes through an internal 
cannula placed in the forearm veins or directly from a vein. The blood was then slightly 
shaken and centrifuged at 5000 rpm for 10 min and the plasma was separated.  The 
obtained plasma samples were stored at −20 °C. The plasma samples were thawed at 
room temperature, spiked with TTT, extracted back, reconstituted and assayed the 
concentration levels. The urine samples of healthy volunteers were collected and spiked 
with TTT tablet dosage form of desired concentration followed by dilution with the diluent. 
The assay results for plasma and urine samples are summarized in Table 5 & 6. 106  R. Yanamandra et al.:   
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Tab. 1.   System suitability, Precision, Linearity, Accuracy, LOD, LOQ and Robustness of 
the proposed method 
System suitability & Precision 
Rt  2.60  Capacity factor   1.60 
N  46728  % RSD (n = 6)   0.63 
USP Tailing   1.14     
Linearity 
Correlation coefficient (r)  0.999  Intercept   8088 
Slope  6622.3  % RSD for Intercept   8.68 
% RSD for slope   0.16     
Accuracy (n = 3)  (% Recovery ± % RSD) 
50%  99.9 ± 0.20 
100%  102.2 ± 0.05 
150%  103.6 ± 0.04 
Mean (n = 3)  101.9 ± 1.83 
Limit of Detection (LOD) and Limit of Quantification (LOQ) 
LOD  0.05 µg mL
−1  LOQ  0.15 µg mL
−1 
Robustness testing
a (n = 3) 
Factor
a  Level  Retention time  Asymmetry  % Assay 
Tolterodine Tartrate 
A: Flow rate (mL min
−1) 
0.25  −1  2.88  1.17  101.50 
0.30  0  2.47  1.14  100.32 
0.35  +1  2.33  1.05  101.41 
Mean ± SD (n = 3)    2.56 ± 0.29  1.12 ± 0.06  101.07 ± 0.67 
B: Buffer concentration 
0.020%   −1  2.41  1.10  98.95 
0.025%   0  2.45  1.14  100.32 
0.030%   +1  2.48  1.16  99.90 
Mean ± SD (n = 3)    2.45 ± 0.04  1.13 ± 0.03  99.72 ± 0.68 
C: Column Temperature 
23 °C  −1  2.50  1.15  98.00 
25 °C  0  2.45  1.12  99.21 
27 °C  +1  2.40  1.09  97.80 
Mean ± SD (n = 3)    2.45 ± 0.05  1.12 ± 0.03  98.33 ± 0.76 
D: Buffer pH 
2.2  −1  2.42  1.08  98.23 
2.3  0  2.45  1.12  99.21 
2.4  +1  2.50  1.15  98.28 
Mean ± SD (n = 3)    2.46 ± 0.04  1.12 ± 0.04  98.57 ± 0.55 
E: % of acetonitrile in the mobile phase (v/v) 
27  −1  2.81  1.17  98.30 
30  0  2.45  1.12  99.21 
33  +1  2.17  1.11  98.88 
Mean ± SD (n = 3)    2.48 ±0.32  1.13 ±0.03  98.80 ± 0.46 
a Three factors were slightly changed at three levels (−1, 0, 1); n…number of determinations; 
Rt…retention time; N…number of theoretical plates; TTT… Tolterodine Tartrate.   A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate  107 
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Results and Discussion 
UPLC Method Development and Optimization  
Development of a rapid, rugged and suitable UPLC method for the quantification of TTT 
required a number of trials to be carried out using different mobile phase compositions. As 
part of the preliminary work, separation was attempted on Acquity BEH C18 (100 mm 
X 2.1 mm, 1.7 μm)  column  with  0.05M  Ammonium  Acetate  in  aqueous  as  buffer  and 
acetonitrile as organic in different gradient programs at a flow rate of 0.3 mL min
−1. Under 
these conditions the peaks found were because of Tartaric acid and Tolterodine free base. 
This was confirmed by separately injecting Tartaric acid and Tolterodine. Attempts were 
also made with 0.05% Formic acid (acidic) and 0.01M Ammonium bicarbonate (basic) with 
pH ranges 3  to  7  were studied to control the dissociation of TTT. To minimize the 
dissociation of TTT, and to improve the peak shape, attempts were made with different 
percentages of TFA buffer and found 0.025% TFA (pH-2.3) as a suitable buffer. Trials 
were also done at different flow rates and different temperatures to optimize the peak 
shape, sensitivity, tailing factor and plate count. 0.025% TFA in aqueous and 0.025% TFA 
in acetonitrile worked out best combination for this method. A mixture of Acetonitrile and 
Water (50:50 v/v) was used as diluent and detection was monitored at 220 nm. 
The typical retention time of TTT is 2.4 min in a total chromatographic run time of 6 min. 
The resolution between TTT and the degradants generated after stress degradation were 
found to be good in the developed RP-UPLC assay method. The system suitability test 
results are summarized in Table 1.  
Representative assay chromatograms of Tolterodine Tartrate (TTT):  
 
Fig. 2.   (A) TTT bulk raw material (B) TTT tablet dosage form 108  R. Yanamandra et al.:   
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Fig. 3.   (C) Blank plasma (D) TTT bulk raw material spiked plasma (E) TTT tablet 
spiked plasma  
 
Fig. 4.   (F) Blank urine sample (G) TTT tablet spiked urine sample   A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate  109 
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Fig. 5.   (H) Sodium hydroxide hydrolysis (I) Hydrogen Peroxide hydrolysis 
Potential interferences from excipients were investigated and  no interferences from 
excipients observed in the chromatography. Analyses were performed for three different 
batches of tablet dosage form (each n = 3). In all batches the contents of TTT were within 
the limits of ≥ 90.0% and ≤ 110.0% (w/w). The assay result for tablet dosage form, plasma, 
and urine samples is summarized in Table 4, 5, & 6. 
Tab. 2.   Linearity curve of Tolterodine Tartrate in RP-UPLC 
 
 
Y = 6622*X - 8088 
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Method Validation  
Precision  
The repeatability was checked by repeatedly injecting (n = 6) solution of TTT and the area 
RSD values for TTT was found to be within 2.0% confirming a suitable precision of the 
method. System suitability and system precision results are summarized in Table 1. Intra-
day and inter-day precision were evaluated by analyzing six replicate injections of assay 
concentration and assay results are summarized in Table 3. 
Tab. 3.   Precision of the proposed UPLC method 
Concentration (µg mL
−1)  Concentration found 
Intra-Day  Inter-Day 
40  40.32 ± 0.35  40.17 ± 0.39 
Mean (n = 3) ± % RSD     
Tolterodine Tartrate  
(µg mL
−1)  
Intermediate precision (n=6) 
Measured conc. ± SD   Recovery (%) ± (%) RSD 
20  20.088 ± 0.39  100.44 ± 0.39 
40  40.276 ± 0.35   100.69 ± 0.35 
60  60.384 ± 0.37   100.64 ± 0.36 
 
Linearity  
The  linear  regression  equation  is  y  =  6622  x  −  8088  and  the  correlation coefficient 
obtained was greater than 0.99 for tablet dosage form which confirmed the linear 
relationship between peak areas and concentrations. Slope and Y-Intercept values were 
6622 and 8088. Linearity was determined for six concentrations of each three replicate 
injections. The linearity test results and linearity curve is summarized in Table 1 & 2.  
Tab. 4.   Assay results for tablet dosage form by the proposed method 
Tolterodine Tartrate (2 mg)  Tolterodine Tartrate found (mg per tablet) 
Mean ± SD (n=3)  Recovery (%) 
Dosage form-B.No: 1  2.027 ± 0.22  101.38 
Dosage form-B.No: 2  2.006 ± 0.06   100.34 
Dosage form-B.No: 3  2.015 ± 0.16  100.76 
 
Tab. 5.   Assay results for plasma samples by the proposed method 
Tolterodine Tartrate  Amount spiked  
(mg) 
Amount found (mg) 
Mean ± SD (n=3)  Recovery (%) 
Bulk-1
st Lot   2  1.924 ± 0.22  96.23 
Bulk-2
nd Lot  2  1.971 ± 0.51  98.53 
Dosage form-B.No: 1  2  1.982 ± 0.31  99.10 
Dosage form-B.No: 2   2  2.005 ± 0.12  100.26 
n…determinations; SD…standard deviation.   A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate  111 
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Accuracy  
The percentage recovery obtained ranged from 90.0% and 110.0% for tablet dosage form. 
The accuracy test results are summarized in Table 1.  
Tab. 6.  Assay results for urine samples by the proposed method 
Tolterodine Tartrate  Amount spiked  
(mg) 
Amount found (mg) 
Mean ± SD (n=3)  Recovery (%) 
Dosage form-B.No: 1  2  1.912 ± 0.26  95.60 
Dosage form-B.No: 2  2  1.956 ± 0.51  97.79 
 
Solution Stability and Mobile phase Stability  
The stability of TTT was assessed during analysis and storage. No significant changes 
were observed in the content of TTT in mobile phase stability experiments. The standard, 
sample solutions prepared in clear  volumetric flasks were stable up to 40 days in 
temperature from 2 to 8 °C. All urine sample solutions were stored in a refrigerator 
between 2 and 8 °C and all plasma sample solutions were stored at −20 °C.  
Specificity 
Degradation was not found in acid hydrolysis (at 80°C, up to 8 hours) which confirms that 
TTT was found to be stable to acidic hydrolysis. The drug was found to be liable to base 
hydrolysis as a total of 73% degradation was found (at 80°C, up to 8 h) with a maximum 
individual degradation product of 72%. Degradation was found in peroxide treatment of 
38.5%, 4%, 14%, 1.28% and 2.06% at relative retention times of 0.32, 0.35, 1.04, 1.62 and 
1.75 min respectively. As more degradation products were found in base hydrolysis and 
peroxide hydrolysis, the hydrolysis conditions were reduced to 3 h by maintaining the 
temperature at 80°C.  Under these conditions no degradation was found in peroxide 
hydrolysis,  whereas 33% degradation was found in base hydrolysis at 0.30 relative 
retention time. The tablet dosage form showed no degradation products under dark, light, 
heat and also in freeze-thaw cycles. Peroxide hydrolysis conditions were established at 
80°C for 6 h, under these conditions 34% total degradation was found out of which 9.11%, 
1.54%, 20.56%, 0.82%, and 1.22% degradation at relative retention of 0.30, 0.34, 1.03, 
1.62, 1.75 min, respectively. The method was specific because degradants were 
separated to base line from main component and the peak purity flag passes for tablet 
dosage form which confirms the method is selective and homogeneity of the drug product. 
Detection and quantification limit 
The analytical sensitivity of the method was anticipated from the signal to noise ratio 3:1 
for LOD and 10:1 for LOQ. The minimum limits at which the analytes could be readily 
detected and quantified were summarized in Table 1. 
Robustness  
Deliberate changes in chromatographic conditions (different flow rate, buffer concentration, 
column temperature, buffer pH, organic solvent %) have no impact on the assay of the 112  R. Yanamandra et al.:   
Sci Pharm. 2012; 80: 101–114 
drug product which shows good robustness of the method. The robustness test results are 
summarized in Table 1.  
Conclusion  
In this study, an accurate, rapid, simple, sensitive, reproducible and stability-indicating 
reversed-phase UPLC method with UV detection was described for the assay of 
Tolterodine Tartrate. The method was fully validated and applied successfully to quantify 
the drug in pharmaceutical dosage form, human plasma and in urine samples. A short 
chromatographic run time of 6 min allows the quantification of Tolterodine Tartrate in bulk 
raw material, tablet dosage form in quality control laboratories, its application in biological 
samples, and is compatible with LC-MS technique where there is no need for traditional 
HPLC methods with complex mobile phase mixtures, long chromatographic run times and 
more solvent consumed methods. The developed RP-UPLC technique will eliminate 
significant time and cost per sample from analytical process while improving the quality of 
results. The proposed method is not hazardous to human health or to the environment and 
is more economic because a large number of samples can be analyzed in a short period of 
time. 
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